Canada Bio-Mfg Facility & COVID-19 reserved vaccines

Canada signs agreements with Pfizer, Novavax, J&J, & Moderna

  • Pfizer, will supply a minimum of 20 million doses of its mRNA-based vaccine candidate, BNT162. Options for obtaining additional doses are under discussion.
  • Johnson & Johnson, will supply up to 38 million doses of its vaccine candidate Ad26.COV2.S.
  • Novavax, will supply up to 76 million doses of its vaccine candidate NVX-CoV2373.
  • Moderna, will supply up to 56 million doses of its vaccine candidate mRNA-1273.

Minister: “Aggressive approach in procuring a portfolio of the most promising vaccine candidates”

According to the Minister of Public Services and Procurement, Anita Anand, “As we continue our work to purchase the supplies and equipment that are necessary to combat the COVID-19 pandemic, we remain equally focused on planning for the future, including securing potential vaccines for Canadians. We are taking an aggressive approach in procuring a portfolio of the most promising vaccine candidates in order to ensure that Canadians will have access to them as quickly as possible once they have been approved.”

Canada already has a $1 billion fund through the ‘Plan to Mobilize Science to fight COVID-19′ to develop a vaccine and treatments, as well as to track the virus. Of this fund, $600 million supports private sector work to develop a vaccine. See Canadian projects in chart below.

None of these vaccines have been approved as yet. They are in various stages of preliminary testing. See chart below.

According to a Canadian government statement, “Health Canada will review the evidence of safety, efficacy, and manufacturing quality for each vaccine to determine whether individual vaccines will be approved for use in Canada, before they are used to vaccinate Canadians.”

Read if you wish the standards testing should meet: COVID-19 vaccine trials should seek worthwhile efficacy Pub: 27 August 2020


Two Million Doses per Month Facility in Montreal at NRC

Canada will rapidly establish a new $126 million bio-manufacturing facility at the Human Health Therapeutics Research Centre (at NRC)  in Montréal.

Through a public-private partnership, the new facility according to the Canadian government “will enable the National Research Council of Canada (NRC) to increase vaccine manufacturing to up to two million doses per month by next year”.

“Canada’s Current Status in the Fight Against COVID-19: Cases leveling, CFR Remains High,” says Civil Society biostatistician.

Canada maintains control over COVID-19 although Infection fatality rate is high Click image to enlarge. Canada maintains control over COVID-19 although Case Fatality Rate (CFR) is high and Infection Fatality Rate (IFR) may be very high. Source: Fred Harris, biostatistician, Civil Society COVID-19 Tracking Group Art/Cropping/Enhancement: Rosa Yamamoto / Feminine-Perspective Magazine

18 Jul 2024

Justin Trudeau, Prime Minister of Canada said Monday that, “As we continue to work together to limit the impact of the COVID-19 pandemic on the health of Canadians, as well as its social and economic effects, we must also maximize our chances of defeating the virus. To do this, we need to invest in the development of several promising vaccines and ensure that we can manufacture and distribute the vaccine to as many Canadians as possible, as quickly as possible. That is how we will move forward on a sustainable path to a full recovery.”

Watch Patty Hajdu, Minister of Health.



Chart: SARS2-CoV-2 vaccine candidates in Phase 1-3 plus significant candidates in pre-clinical R&D


CandidateSponsorTrial PhaseInstitution
bacTRL-SpikeSymvivoPre-clinicalSymvivo Corporation
of Pittsburgh School of Medicine
Pre-clinicalUniversity of Pittsburgh
V591University of Pittsburgh’s Center
for Vaccine Research
Pre-clinicalUniversity of PittsburghThemis
Ii-Key peptide COVID-19 vaccineGenerex BiotechnologyPre-clinicalGenerex
Recombinant vaccineVaxartPre-clinicalVaxart
LineaDNATakis BiotechPre-clinicalTakis Biotech
AdCOVIDAltimmunePre-clinicalUniversity of Alabama at
Protein subunit vaccineUniversity of Saskatchewan Vaccine
and Infectious Disease Organization-International Vaccine Centre
Pre-clinicalUniversity of Saskatchewan Vaccine
and Infectious Disease Organization-International Vaccine Centre
Adenovirus-based vaccineImmunityBioNantKwestPre-clinical
AAVCOVIDMassachusetts Eye and Ear; Massachusetts General Hospital;
University of Pennsylvania
Recombinant vaccineSanofiTranslate
HaloVaxVoltron Therapeutics, Inc.; Hoth Therapeutics, Inc.Pre-clinicalMGH Vaccine and
Immunotherapy Center
mRNA-based vaccineChulalongkorn University’s Center
of Excellence in Vaccine Research and Development
HDT-301University of WashingtonNational
Institutes of Health Rocky Mountain Laboratories
Bio Corp
gp96-based vaccineHeat BiologicsPre-clinicalUniversity of Miami Miller School
of Medicine
ChAd-SARS-CoV-2-SWashington University School
of Medicine in St. Louis
Pre-clinicalWashington University School
of Medicine in St. Louis
Inactivated vaccineWuhan
Institute of Biological Products
National Pharmaceutical Group (Sinopharm)
Phase 3Henan Provincial Center for Disease Control and Prevention
CoronaVacSinovacPhase 3Sinovac Research and
Development Co., Ltd.
mRNA-1273ModernaPhase 3
Kaiser Permanente Washington Health Research Institute
Ad5-nCoVCanSino BiologicsPhase 3Tongji Hospital; Wuhan,
NVX-CoV2373NovavaxPhase 2bNovavax
Bacillus Calmette-Guerin (BCG) live-attenuated vaccineUniversity of Melbourne and
Murdoch Children’s Research Institute
University Medical Center
Lab at Massachusetts General Hospital
Phase 2/3University of Melbourne and
Murdoch Children’s Research Institute
University Medical Center
Lab at Massachusetts General Hospital
AZD1222/CovishieldThe University of OxfordAstraZenecaIQVIA;
Serum Institute of India
Phase 2/3The University of Oxfordthe
Jenner Institute
BNT162PfizerBioNTechPhase 2/3Multiple study sites in Europe and North America
Adjuvant recombinant vaccine candidateAnhui Zhifei Longcom Biopharmaceutical, Institute of Microbiology of
the Chinese Academy of Sciences
Phase 2
ZyCoV-DZydus CadilaPhase 2Zydus Cadila
CovaxinBharat BiotechNational
Institute of Virology
Phase 2
BBIBP-CorVBeijing Institute of Biological Products; China
National Pharmaceutical Group (Sinopharm)
Phase 1/2Henan Provincial Center for Disease Control and Prevention
GRAd-COV2GenexinePhase 1/2
Sputnik VGamaleya Research Institute, Acellena Contract Drug Research and
Phase 1/2Various
Self-amplifying RNA vaccineImperial College LondonPhase 1/2
Imperial College London
LUNAR-COV19Arcturus Therapeutics and Duke-NUS
Medical School
Phase 1/2Duke-NUS Medical School,
INO-4800Inovio PharmaceuticalsPhase 1/2Center for Pharmaceutical Research,
Kansas City. Mo.; University
of Pennsylvania
, Philadelphia
Ad26.COV2-SJohnson & JohnsonPhase 1/2Johnson & Johnson
mRNA-based vaccineCureVacPhase 1CureVac
Dynavax and
Xiamen Innovax
Phase 1Linear Clinical Research
COVAX-19Vaxine Pty Ltd.Phase 1Royal Adelaide Hospital
Plant-based adjutant COVID-19 vaccine candidateMedicagoGSKDynavaxPhase 1Medicago
Molecular clamp vaccineCSLThe
University of Queensland
Phase 1
V590MerckIAVIPhase 1
GRAd-COV2ReiTheraLeukocareUnivercellsPhase 1
Lazzaro Spallanzani National Institute for Infectious Diseases
AdimrSC-2fAdimmunePhase 1Adimmune
mRNA lipid nanoparticle (mRNA-LNP) vaccineCanSino BiologicsPrecision
Early research


Chart Data Source: Regulatory Affairs Professionals Society.


Read also:

Civil Society aims at children to demystify SARS2 vaccines

“Do Minions Catch The Virus?” asked the nurse at a remote clinic while speaking to some children. “Not if they do these simple things,” she went on. Hey kids. Funny Minions, silly Gru, some moms, doctors and nurses explain social